Tarsus Pharmaceuticals (TARS) Stock Analysis & Winston Score

Tarsus Pharmaceuticals is a small biotech company that makes prescription eye care medicines. Its main product is Xdemvy (lotilaner ophthalmic solution), a prescription eye drop approved by the FDA in 2023 to treat Demodex blepharitis — a common eyelid condition caused by tiny mites. The company sells primarily to eye care professionals like ophthalmologists and optometrists in the United States. Tarsus earns money by selling Xdemvy through pharmacies and specialty distributors, with doctors writing prescriptions for patients. The company operates almost entirely in the U.S. market and is still relatively small, with Xdemvy being its first and only commercial product. Its 90% gross margin reflects the high pricing power typical of specialty pharmaceuticals, but the company is not yet profitable as it spends heavily on sales and marketing to build awareness. The key growth driver is expanding Xdemvy's adoption among the estimated 25 million Americans thought to have Demodex blepharitis, while the main risk is dependence on a single product.